Antibodies, also known as immunoglobulins (Ig), were first described in 1890. They are large, Y-shaped glycoproteins that the immune system uses to recognize and neutralize foreign antigens, such as bacteria or viruses. Antibodies can bind to virtually any non-self surface with exceptional specificity and high affinity. These properties make antibodies not only crucial for immunity but also indispensable tools for biomedical research, diagnostics, and treatment.
(Data source: Bitencourt ALB, et al. Int J Mol Sci. 2020)
Recombinant antibodies are antibodies that are obtained by cloning the gene sequence encoding the antibody into an expression plasmid that allows unlimited production and then recombinantly expressing and purifying the antibody. Compared with traditional antibodies, recombinant antibodies have many advantages, including clear sequencing sequences, reliable recombinant expression levels, and the opportunity to enhance their effectiveness through various forms of antibody engineering.
(Data source: Trimmer JS. Curr Protoc Neurosci. 2020)
The use of recombinant antibodies in biomedical research is also steadily increasing. This is partly due to advances in recombinant antibody development technology, which has reduced the investment required to develop recombinant antibodies. Furthermore, with the widespread adoption of hybridoma and mass spectrometry sequencing, the resequencing of previously identified antibody clones and the inclusion of these sequences in various databases have resulted in an increasing number of antibody sequences being reported. Wuhan MysBio, leveraging its two core platforms: the mammalian cell protein expression platform and the B cell antibody development platform, offers both de novo recombinant antibody development services and the modification and recombinant expression of known sequence antibodies, leveraging publicly available database resources.
We meet your recombinant antibody needs through:
Produce large quantities of antibodies (from 1 mg to >1 g) from a single batch and ensure antibody quality control and characterization;
Ensure the production and purification of antibodies of various species (rabbit, mouse, rat, human, etc.) (IgG or IgM );
Strict endotoxin control (<1 EU/ mg);
Low protease, host DNA and RNAse residues;
(>95% purity) for in vivo animal studies;
The Wuhan Mabnus Bio R&D team has more than ten years of experience in recombinant protein and recombinant antibody research and development, focusing on eukaryotic mammalian cell recombinant protein expression and single B cell recombinant rabbit monoclonal antibody development, providing simpler and more efficient recombinant protein and recombinant antibody development services.
